PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
-0.03
%
−8,11%
Latest
0.34
High
0.371
Low
0.301
Volume
15 303
Turnover (SEK)
5 656
Market Value (MSEK)
18,3
Time (Latest trade)

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Björn Sivik (tf)

Board

  • Bo Wennergren
  • Björn Sivik
  • Staffan Skogvall
  • Stefan Ahlfors

Largest Owners

Name Capital % Votes % Date
Staffan Skogvall 49,14 49,14 2025-06-26
Vict Th Engwalls Stiftelse 3,33 3,33 2025-06-26
Arne Arvidsson 2,11 2,11 2025-06-26
Arne Skogvall 2,08 2,08 2025-06-26
Avanza Pension 1,19 1,19 2025-06-26
Nordnet Pensionsförsäkring 0,85 0,85 2025-06-26
Tommy Johansson 0,81 0,81 2025-06-26
Staffan Engelbert Bodén 0,66 0,66 2025-06-26
Monica Billgert 0,54 0,54 2025-06-26
Investment Aktiebolaget Balticum 0,49 0,49 2025-06-26
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2025-07-15 Årsstämma 2024

  • 2025-08-21 Delårsrapport 2025-Q2

  • 2025-11-20 Delårsrapport 2025-Q3

  • 2026-02-19 Bokslutskommuniké 2025

Annual reports, prospectus etc.